Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine;Tratamento da síndrome do intestino irritável pós-infecciosa e da síndrome do intestino irritável não-infecciosa com mesalazina

Arquivos de Gastroenterologia

Volumn 48, Issue 1, 2011, Pages 36-40

  Bafutto, Mauro ^a   de Almeida, José Roberto ^b   Leite, Nayle Vilela ^c   Oliveira, Enio Chaves ^d   Gabriel Neto, Salustiano ^d   Rezende Filho, Joffre ^b  

^a Faculdade de Medicina   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Instituto Goiano de Gastroenterologia   (Brazil)

^d UFGO   (Brazil)

Author keywords

Inflammatory bowel diseases; Irritable bowel syndrome; Mesalamine

Indexed keywords

MESALAZINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ARTICLE; COLITIS; DIARRHEA; DRUG EFFECT; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONOSCOPY; DIARRHEA; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MESALAMINE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79956310821     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032011000100008     Document Type: Article

References (28)

1. Akiho M, Deng Y, Blennerhassett P, Kanbayashi H, Collins SM. Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction. Gastroenterology. 2005;129:131-41.
2. Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther. 2004;2:1-9.
3. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Corinaldesi R. Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues. Dig Dis. 2007;25:245-8.
4. Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther. 1999;13:1397-402.
5. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778-83.
6. Connor BA. Sequelae of traveler's diarrhea: focus on post-infectious irritable bowel syndrome. Clin Infect Dis. 2005;41:S577-86.
7. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut. 2002;51:i67-71.
8. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol. 2003;98:1578-83.
9. Dunlop SP, Colemam NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3:349-57.
10. Forbes A, Cartwright A, Marchant S, Mcintyre P, Newton M. Oral, modified-release mesalazine formulations-proprietary versus generic [review article]. Aliment Pharmacol Ther. 2003;17:1207-14.
11. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1991;36:179-84.
12. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut. 1999;44:400-6.
13. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM. Increased rectal mucosal expression of interleukin 1β, in recently acquired post-infectious irritable bowel syndrome. Gut. 2003;52:523-6.
14. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA. 2004;292:852-8.
15. Liptay S, Bachem M, Häcker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol. 1999;128:1361-9.
16. MacDermott RP. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am J Gastroenterol. 2000;95:3343-5.
17. Marshall JK, Thabane M, Garg AX, Clark W, Meddings J, Collins SM. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther. 2004;20:1317-22.
18. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut. 2002;51:410-3.
19. Reinacher-Schick A, Seidensticker F, Petrasch S, Reiser M, Philippou S, Theegarten D, Freitag G, Schmiegel W. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy. 2000;32:245-54.
20. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
21. Small RE, Schraa CC. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease. Pharmacotherapy. 1994;14:385-98.
22. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804-11.
23. Spiller RC. Post-infectious irritable bowel syndrome. Gastroenterology. 2003;124:1662-71.
24. Spiller R, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol. 2006;22:13-7.
25. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol. 2007;42:41-7.
26. Tromm A, Griga T, May B. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology. 1999;46:3124-35.
27. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998;101:1163-74.
28. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119:1209-18.